We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Kite Grabs Refuge License for New CAR-T Platform
Gilead subsidiary Kite has acquired an exclusive global license for Refuge Biotechnologies’ second-generation CAR-T gene editing platform to develop blood cancer treatments.